Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.

@article{sterroos2016CombinationSI,
  title={Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.},
  author={A {\"O}sterroos and Muhammad Kashif and Caroline Haglund and Kristin Blom and Martin H{\"o}glund and Charlotte Andersson and M G Gustafsson and Anna I. K. Eriksson and Rolf Larsson},
  journal={Biochemical pharmacology},
  year={2016},
  volume={118},
  pages={40-49}
}
Cytogenetic lesions often alter kinase signaling in acute myeloid leukemia (AML) and the addition of kinase inhibitors to the treatment arsenal is of interest. We have screened a kinase inhibitor library and performed combination testing to find promising drug-combinations for synergistic killing of AML cells. Cytotoxicity of 160 compounds in the library InhibitorSelect™ 384-Well Protein Kinase Inhibitor I was measured using the fluorometric microculture cytotoxicity assay (FMCA) in three AML… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS